{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"USBrandName","name":"Imdelltra"},{"type":"Synonym","name":"tarlatamab"},{"type":"CodeName","name":"AMG 757"},{"type":"CodeName","name":"AMG-757"},{"type":"CodeName","name":"AMG757"},{"type":"Synonym","name":"bispecific T-cell engager antibody AMG 757"},{"type":"Synonym","name":"BiTE antibody AMG 757"},{"type":"Synonym","name":"DLL3/CD3-directed bispecific T-cell engager antibody AMG 757"},{"type":"Synonym","name":"anti-DLL3 x anti-CD3 BiTE AMG 757"}],"definition":{"html":"A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) fused to one that is directed against the CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, tarlatamab binds to both the CD3 antigen on cytotoxic T lymphocytes (CTLs) and the DLL3 antigen found on DLL3-expressing tumor cells. This activates and redirects CTLs to DLL3-expressing tumor cells, which results in the CTL-mediated cell death of DLL3-expressing tumor cells. DLL3, a Notch pathway protein, is overexpressed on a variety of cancer cell types. It plays a key role in embryonic development and in tumor initiation and proliferation.","text":"A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) fused to one that is directed against the CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, tarlatamab binds to both the CD3 antigen on cytotoxic T lymphocytes (CTLs) and the DLL3 antigen found on DLL3-expressing tumor cells. This activates and redirects CTLs to DLL3-expressing tumor cells, which results in the CTL-mediated cell death of DLL3-expressing tumor cells. DLL3, a Notch pathway protein, is overexpressed on a variety of cancer cell types. It plays a key role in embryonic development and in tumor initiation and proliferation."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/tarlatamab-dlle","text":"Tarlatamab-dlle"},"nciConceptId":"C175858","nciConceptName":"Tarlatamab","termId":792376,"name":"tarlatamab-dlle","firstLetter":"t","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"tarlatamab"}],"links":null}